# TPO-RA Plus Baricitinib vs. TPO-RA for ITP

> **NCT07669675** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 100 (estimated)

## Conditions studied

- ITP - Immune Thrombocytopenia

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** TPO-RA

## Key facts

- **NCT ID:** NCT07669675
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07669675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07669675, "TPO-RA Plus Baricitinib vs. TPO-RA for ITP". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07669675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*